<DOC>
	<DOCNO>NCT00479050</DOCNO>
	<brief_summary>Combined chemoembolization Radiofrequency ablation hepatocellular carcinoma great 3 cm , ablation volume coagulation necrosis significantly increase , may enable effective treatment patient HCC great 3 cm .</brief_summary>
	<brief_title>Combination Chemoembolization Radiofrequency Ablation Hepatocellular Carcinoma Greater Than 3 cm</brief_title>
	<detailed_description>To assess whether effectiveness combination transcatheter arterial chemoembolization ( TACE ) radiofrequency ablation ( RFA ) superior TACE RFA alone treatment patient hepatocellular carcinoma ( HCC ) great 3 cm analyze factor affect outcomes . The patient HCC 3 few lesion , 3cm great diameter enter randomize controlled trial . The primary end point survival , secondary end point tumor response .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Eligibility criterion : 1 . Not indicated resection , 2 . Liver function ChildPugh class A B , 3 . 3 few lesion , 3 cm great 7.5 cm less great diameter , 4 . No portal vein involvement extrahepatic metastasis , 5 . Lesions locate least 5mm away hepatic hilum gall bladder common bile duct , 6 . Platelet count≥6.0×103/mm3 prothrombin activity≥60 % , 7 . No previous HCC treatment . Exclusion criterion : 1 . Encephalopathy , 2 . Refractory ascites , 3 . Active gastrointestinal bleeding , 4 . Renal failure .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Hepatocellular carcinoma , treatment</keyword>
</DOC>